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Introduction
1. INTRODUCTION 
1.1. ANALYTICAL CHEMISTRY
Analytical chemistry is a branch of chemistry, which covers a series of subjects covering
the  science  of  chemical  separation,  identification,  detection  and  measurement  of  a
sample. It is mainly involved in the qualitative identification or detection of compounds
and quantitative measurement of the substances present in the bulk and pharmaceutical
preparation.  Qualitative  identification  provides  information  about  the  identity  of  an
atomic, molecular or bimolecular species. Quantitative measurement provides numerical
information as to the relative amounts of species.
METHODS OF DETECTING ANALYTES
1. Physical means
 Mass
 Color
 Refractive index
 Thermal conductivity
2. With electromagnetic radiation (Spectroscopy)
 Absorption
 Emission
 Scattering
3. By an electric charge
 Electrochemistry
 Mass spectrometry
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     The newer methods for separating and determining chemical species are known 
collectively as instrumental methods of analysis. Most of the instrumental methods fit 
into one of the three following categories viz., spectroscopy, electrochemistry and 
chromatography.
ADVANTAGES OF INSTRUMENTAL METHODS
 Small samples can be used.
 High sensitivity is obtained.
 Measurements obtained are reliable. 
 Determination is very fast.
 Even complex samples can be handled easily.
LIMITATIONS OF INSTRUMENTAL METHODS 
 An initial calibration is required.
 Sensitivity and accuracy depends on the instrument.
 Cost of the equipment is large.
 Concentration range is limited.
 Specialized space is required.
1.2. PRINCIPLE TYPES OF CHEMICAL INSTRUMENTATION
SPECTROMETRIC TECHNIQUES
i. Ultraviolet and visible spectroscopy
ii. Fluorescence and phosphorescence spectroscopy
iii. Atomic spectroscopy
iv. Infrared spectroscopy
v. Raman spectroscopy
vi. X-Ray spectroscopy
vii. Radiochemical Techniques including activation analysis
viii. Nuclear Magnetic Resonance spectroscopy
ix. Electron Spin Resonance spectroscopy
ELECTROCHEMICAL TECHNIQUES 
i. Potentiometry
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ii. Voltametry
iii. Stripping Techniques
iv. Amperometric Techniques
v. Electrogravimetry
vi. Conductance Techniques
CHROMATOGRAPHIC TECHNIQUES
i. Gas Chromatography
ii. High Performance Liquid Chromatography
iii. High Performance Thin  Layer Chromatography
MISCELLANEOUS TECHNIQUES
i. Thermal analysis
ii. Mass spectroscopy
iii. Kinetic Techniques
HYPHENATED TECHNIQUES
i. Gas Chromatography - Mass spectroscopy (GC-MS) 
ii. Inductivity coupled plasma -Mass spectroscopy (ICP – MS) 
iii. Gas Chromatography- Infrared spectroscopy (GC-IR) 
iv.  Mass spectrometry (MS-MS)
1.3   PRELIMINARY STUDIES  
a) Determination of melting point.
b) Determination of wavelength of maximum absorption.
1.3.1. MELTING POINT: 
A melting point can be used to identify a substance and to get an indication of its purity.
The melting point (or freezing point) of a solid is the temperature at which the solid exists
in equilibrium with its liquid state under an external pressure of one atmosphere. Both the
melting point  range (the interval  between the beginning of  liquefaction and complete
liquefaction) and the temperature of complete liquefaction are valuable indicators of the
purity of the solid compound. A pure crystalline organic compound usually possesses
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a sharp melting point and it  melts completely over a narrow temperature range of not
more than 0.5-1.0oC, provided good technique is followed. The presence of even small
amounts of impurities usually produces a depression of the temperature at which melting
is  complete and usually  produces  a  marked increase in  the  width  of  the  melting
point range.
Procedure: Fill a melting point capillary tube with the sample of linagliptin by thrusting
the open end into the powder several times. In order to work the plug of solid material
down to  the  sealed end of  the capillary,  tap the  sealed end on the  table.  Repeat  the
procedure  until  the  tube  contains  a 3  mm  column  of  densely  packed  powder in  the
bottom. Place the capillary in the melting point apparatus through one of the side tubes so
that the sealed end of the capillary is dipped in liquid parrafin.Gradually the temperature
raises and substance in the capillary tube starts melting, note the temperature.
1.3.2. DETERMINATION OF WAVELENGTH OF MAXIMUM ABSORPTION: 
     In  analyzing a  new sample,  a  chemist  first  determines  the  sample's  absorbance
spectrum. The absorbance spectrum shows how the absorbance of light depends upon the
wavelength of the light. The spectrum itself is a plot of absorbance vs wavelength and is
characterized by the wavelength (λmax) at which the absorbance is the greatest. The value
of λmax is  important  for  several  reasons.  This  wavelength  is  characteristic  of  each
compound and provides information on the electronic structure of the analyte. In order to
obtain the highest sensitivity and to minimize deviations from  Beer's  Law.  Analytical
measurements are made using light with a wavelength of λmax.
Procedure: An appropriate concentration of sample solution (20µg/mL) was scanned to
determine λmax  in UV-Visible spectrophotometer. 
1.4ANALYTICAL METHOD DEVELOPMENT:
Methods  are  developed  for  new  products  when  no  official  methods  are  available.
Alternate methods for existing (non-pharmacopoeial) products are developed to reduce
the cost and time for better precision and ruggedness. Trial runs are conducted, method is
optimized  and  validated.  When alternate  method proposed  is  intended  to  replace  the
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existing procedure,comparative laboratory data including merits/demerits should be made
available.
STEPS INVOLVED IN METHOD DEVELOPMENT:
Documentation starts at the very beginning of the development process. A system for full
documentation of development studies must be established. All data to these studies must
be recorded in laboratory notebook or an electronic database.
ANALYTE STANDARD CHARACTERIZATION:
1. All  known  information  about  the  analyte  and  its  structure  is  collected  i.e.,
physical and chemical properties.
2. The standard analyte (100% purity) is obtained. Necessary arrangement is made
for the proper storage(refrigerator,desiccators and freezer).
METHOD REQUIREMENTS:
The goals or requirements of the analytical method that need to be developed are defined
below. The required detection limits, selectivity, linearity, range, accuracy, and precision
are defined.
LITERATURE SEARCH AND PRIOR METHODOLOGY:
The literature for all types of information related to the analyte is surveyed, for synthesis
physical  and  chemical  properties,  solubility,  relevant  analytical  methods  in  books,
periodicals, chemical manufacturers and regulatory agency compendia such as USP/ NF
are  reviewed.  Chemical  abstracts  service  (CAS)  automated  computerized  literature
searches are convenient for literature survey.
CHOOSING A METHOD:
     Based on the information of analyte properties and methods reported literature method
is developed. The methods are modified wherever necessary. Sometimes it is necessary to
acquire additional  instrumentation to  reproduce,  modify,  improve  or  validate  existing
methods for in-house analytes and samples.
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If there are no prior methods for the analytein the literature, from analogy the compounds
that are similar in structure and chemical properties are investigated and are worked out. 
INSTRUMENTAL SETUP AND INITIAL STUDIES:
The  required  instrumentation  is  arranged,  installed,  operational  and  performance
qualification of instrumentation using laboratory standard operating procedures (SOP’s)
is verified.
     During the analytical method development analytical grade consumables (solvents,
filters and gases) are used, and high quality columns and instruments are employed.
Theanalyte standard in a suitable solvent  is  prepared.  It  is  important  to start  with an
authentic, known standard rather than with a complex sample matrix. If  the sample is
extremely close to the standard (e.g., bulk drug), then it is possible to start work with the
actual sample.
OPTIMIZATION
During optimization one parameter is changed at a time and set of conditions are isolated,
rather  than using a trial  and error  approach.  Work has  been done from an organized
methodical plan, and every step is documented in a lab notebook.
DOCUMENTATION OF ANALYTICAL FIGURES OF MERIT:
The originally determined analytical figures of merit are limit of quantification (LOQ),
Limit of detection (LOD), linearity, time per analysis, cost, sample preparation etc., are
documented.
EVALUATION OF METHOD DEVELOPMENT WITH ACTUAL SAMPLES:
The sample solution should lead to unequivocal, absolute identification of the analyte
peak of interest apart from all other matrix components.
DETERMINATION  OF PERCENT  RECOVERY OF ACTUAL SAMPLE  AND
DEMONSTRATION OF QUANTITATIVE SAMPLE ANALYSIS:
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Percent recovery of spiked, authentic standard analyte into a sample matrix that is shown
to contain no analyte is determined. Reproducibility of the recovery (average, standard
deviation)from sample to sample and whether recovery has been optimized or not has
been  shown.  It  is  not  necessary to  obtain  100% recovery as  long  as  the  results  are
reproducible and known with a high degree of certainty.
STABILITY-INDICATING METHOD DEVELOPMENT
A stability-indicating method is defined as an analytical method that accurately quantities
the active ingredients without  interference from degradation products,.  A method that
accurately quantititates significant degradant may also be considered stability-indicating.
A proactive approach to developing a stability indicating HPLC method should involve
forced degradation at the early stages of development with the key degradation samples
used in the method development process.
If forced degradation studies are performed early, method development and identification
of primary degradation products and unknown impurities can be run in parallel. Using
this  process  a  validated  HPLC  analytical  assay  mechanism  of  degradation  and  the
impurity/degradant  information  for  filing  can  all  be  generated  without  delays  in  the
project timeline.
1.5. ANALYTICAL METHOD VALIDATION
     According to the International Conference on Harmonisation (ICH) method validation
can be defined as “Establishing documented evidence, which provides a high degree of
assurance that  a specific activity will  consistently produce a desired result  or product
meeting is predetermined specifications and quality characteristics”. Method validation is
an integral part of the method development it is the process by which a method is tested
by the developer or user for reliability, accuracy and preciseness of its intended purpose
and demonstrating that analytical procedure are suitable for their intended use that they
support the identity, quality ,purity, and potency of the drug substances and drug products
data thus generated become part of the method validation package submitted to Center
for Drug Evaluation and Research (CDER). 
           Methods should be reproducible when used by other analysts, on other equivalent
equipment, on other days or locations, and throughout the life of the drug product. Data
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that are generated for acceptance, release, and stability or pharmacokinetic will only be
trust  worthy  if  the  methods  used  to  generate  the  data  are  reliable.  The  process  of
validation and method design also should be clearly in the development cycle before
important data are generated. Validation should be on going in the form of re-validation
with method changes.
 Though many types of HPLC techniques are available the most commonly used method,
the reversed phase HPLC with UV detection, is selected to illustrate the parameters for
validation. The criteria for the validation of this technique can be extrapolated to other
detection methods and chromatographic techniques. In this technique all the variables of
the  method  should be  considered,  including sampling procedure,  sample  preparation,
chromatographic separation, and detection data evaluation. 
Analytical parameters includes namely
I. System suitability
II. Accuracy
III. Precision
IV. Linearity
V. Specificity/selectivity
VI. Limit of Detection 
VII. Limit of Quantification
VIII. Robustness
1. SYSTEM SUITABILITY:
According to USP system suitability tests are an integral part of chromatographic method.
These tests are used to verify that the resolution and reproducibility of the system that are
adequate for the analysis to be performed.The purpose of the system suitability test is to
ensure that  the  complete testing system (including instrument,  reagents,  columns and
analysts) is suitable for the intended application.
During  the  early  stage  of  the  method  development  process  some  of  the  more
sophisticated system suitability tests may not be practical due to the lack of experience
with the method. In this stage, usually a more “generic” approach is used. For example,
evaluation  of  the  tailing  factor  to  check  chromatographic  suitability  and  replicate
injections of the system suitability solution to check injection precision may be sufficient
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for an HPLC assay. As the method matures more experience is acquired for this method,
a more sophisticated system suitability test may be necessary.
System suitability is the checking of a system to ensure system performance before or
during  the  analysis  of  unknowns.  Parameters  such  as  plate  count,  tailing  factors,
resolution and reproducibility (% RSD of retention time and peak area for six repetitions)
are  determined  and  compared  against  the  specifications  set  for  the  method.  These
parameters  are  measured  during  the analysis  of  system suitability “sample” that  is  a
mixture  of  main  components  and  expected  by-products.  The  terms  that  should  be
measured  and  their  recommended  limits  obtained  from  the  analysis  of  the  system
suitability  sample  as  per  current  ICH  guidelines  on  “validation  of  chromatographic
methods” were given below
Acceptance criteria:
Parameter Recommendation
Capacity Factor (k) The peak should be well-resolved from
other peaks and the void volume , generally
k >2.0
Repeatability RSD≤2% for N≥5 is desirable.
Relative retention Not essential as long as the resolution is
stated.
Tailing factor(T) T of ≤2
Theoretical plates (N) N> 2000
2. ACCURACY 
The accuracy of an analytical procedure expresses the closeness of agreement between
the value which is accepted either as a conventional true value or an accepted reference
value  and  the  value  found(15).  This  is  sometimes  termed  as  “trueness”.  The  different
methods for analysis of accuracy are
i. Analyzing sample of known concentration and comparing the measured value to
the true value.  However,  a  well  characterized sample (e.g.  reference standard)
must be used.
ii. Spiked – placebo (product  matrix) recovery method:  In  this method,  a  known
amount  of  pure  active  constituent  is  added  to  formulation  blank  sample  that
contains  all  other  ingredients  except  active  ingredient,  resulting  mixture  is
assayed, and the results obtained are compared with the expected result.
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iii. Standard addition method: In this method initially a sample is  assayed, then a
known amount of pure active constituent is added to the sample, and the sample is
again assayed. The difference between the results of the two assays is compared
with the expected answer.
     In both methods (spiked – placebo recovery and standard addition method), recovery
is defined as the ratio of the observed result to the expected result and expressed as a
percentage. The accuracy of a method may vary across the range of possible assay values
and therefore must be determined at several different fortification levels. The accuracy
should cover at least 3 concentrations (80,100, 120%) in the expected range. Accuracy
may also be determined by comparing   test results with those obtained using another
validated test method.
Acceptance criteria:The mean % recovery at each experiment should not be less than
98.0% and not more than 102.0%.
3. PRECISION 
The precision of an analytical procedure expresses the degree of closeness of agreement
(degree of scatter) between a series of measurements obtained from multiple sampling of
the same homogeneous sample under the prescribed conditions.
Precision may be considered at three levels:
I. System precision (Repeatability)
II. Method precision (Reproducibility)
III. Intermediate precision (Ruggedness)
• Repeatability 
Repeatability should be obtained when the analysis is carried out in laboratory by an
operator using equipment over a relatively short time span. They must contain 
a) A minimum of 9 determinations covering the specified range for the procedure (e.g., 3
concentrations/3 replicates each); or 
b) A minimum of 6 determinations at 100% of the test concentration. 
• Intermediate Precision 
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The  extent  to  which  intermediate  precision  should  be  established  depends  on  the
circumstances under which the procedure is intended to be used. The applicant should
establish  the  effects  of  random  events  on  the  precision  of  the  analytical  procedure.
Typical  variations  to  be  studied  include  days,  analysts,  equipment,  etc.  It  is  not
considered  necessary to  study these  effects  individually.  The  use  of  an  experimental
design (matrix) is encouraged. 
• Reproducibility
Reproducibility is assessed by means of an inter-laboratory trial. Reproducibility should
be considered in case of the standardization of an analytical procedure, for instance, for
inclusion of  procedures  in pharmacopoeias.  These data are not  part  of  the marketing
authorization dossier. 
The  standard  deviation,  relative  standard  deviation  (coefficient  of  variation)  and
confidence interval should be reported for each type of precision investigated. 
Acceptance criteria:% RSD of peaks areas should not be more than 2.0%
4. LINEARITY 
The linearity of an analytical procedure is its ability within a given range to obtain test
results which are directly proportional to the concentration of analyte in the sample. A
linear relationship should be evaluated across the range of the analytical procedure. It
may be  demonstrated  directly on  the  drug  substance  by dilution  of  a  standard  stock
solution using the proposed procedure(11). 
Linearity should be evaluated by visual inspection of a plot of signals as a function of
analyte concentration or content. If  there is a linear relationship, test results should be
further  evaluated by appropriate  statistical  methods,  for  example,  by calculation of  a
regression line by the method of least squares. In some cases, to obtain linearity between
assays  and  sample  concentrations,  the  test  data  may  need  to  be  subjected  to  a
mathematical transformation prior to the regression analysis. Data from the regression
line itself may be helpful to provide mathematical estimates of the degree of linearity. For
the  establishment  of  linearity,  a  minimum  of  5  concentrations  calibration  curve  is
recommended.(35)
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Some analytical procedures, such as immunoassays, do not demonstrate linearity after
any  transformation.  In  this  case,  the  analytical  response  should  be  described  by  an
appropriate function of the concentration of an analyte in a sample. 
Acceptance criteria: Correlation coefficient should be not less than 0.999.
5.SPECIFICITY /SELECTIVITY: 
The  terms  selectivity  and  specificity  are  often  used  interchangeably.  According  to
International Conference on Harmonisation (ICH), the term specific generally refers to a
method that produces a response for a single analyte only while the term selectivity refers
to a method that provides responses for a number of chemical entities that may or may
not  be distinguished  from each  other.  If  the response  is  distinguished  from all  other
responses,  the method is  said  to be  selective.  Since there are  very few methods that
respond to only one analyte, the term selectivity is usually more appropriate.
The analyte should have no interference from other extraneous components and be well
resolved from them. A representative HPLC chromatogram or profile should be generated
and submitted to show that the extraneous peaks either by addition of known compounds
or samples from stress testing are baseline resolved from the parent analyte
6. DETECTION LIMIT 
The limit  of  detection of  an individual  analytical  procedure  is  the lowest  amount  of
analyte in a sample which can be detected but not necessarily quantitated as an exact
value.
Based on the standard deviation of the response and the Slope the LOD may be expressed
as 
LOD = 3.3   σ 
S 
Where σ = The standard deviation of the response 
          S = The slope of the calibration curve 
The slope S may be estimated from the calibration curve of the analyte. The estimate of σ
may be carried out in a variety of ways, for example
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1. Based on the standard deviation of the blank
Measurement  of  the  magnitude  of  analytical  background  response  is  performed  by
analyzing an appropriate number of blank samples and calculating the standard deviation
of these responses. 
2. Based on the calibration curve 
A specific calibration curve should be studied using samples containing an analyte in the
range  of  detection  limit.  The  residual  standard  deviation  of  a  regression  line  or  the
standard  deviation  of  y-intercepts  of  regression  lines  may  be  used  as  the  standard
deviation. 
7. QUANTITATION LIMIT 
The  quantitation  limit  of  an  individual  analytical  procedure  is  the  lowest  amount  of
analyte in a sample which can be quantitatively determined with suitable precision and
accuracy. 
Based on standard deviation of the response and of the slope, the Quantitation limit (QL)
may be
expressed as
LOQ  =10   σ 
                                         S 
where σ = The standard deviation of the response 
           S = The slope of the calibration curve 
8. ROBUSTNESS 
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    The robustness of an analytical  procedure is  a measure of its  capacity to remain
unaffected  by small,  but  deliberate  variations  in  method  parameters  and  provides  an
indication of its reliability during normal usage.
The evaluation of robustness should be considered during the development phase and
depends on the type of procedure under study. It should show the reliability of an analysis
with respect to deliberate variations in method parameters. 
      If measurements are susceptible to variations in analytical conditions, the analytical
conditions should be suitably controlled or a precautionary statement should be included
in the procedure. One consequence of the evaluation of robustness should be that a series
of system suitability parameters is established to ensure that the validity of the analytical
procedure is maintained whenever used. 
In  the case of  liquid chromatography,  examples of  typical  variations are influence of
variations of pH in a mobile phase, influence of variations in mobile phase composition,
different columns (different lots and/or suppliers), temperature, flow rate.
9. SOLUTION STABILITY
     To generate reproducible and reliable results, the samples, standards and reagents used
for HPLC method must be stable for a reasonable time (e.g., one day, one week, one
month, depending upon the need). Therefore, a few hours of standard and sample solution
stability  can  be  required  even  for  short  separation.  When  more  than  one  sample  is
analyzed (multiple lots of one sample or samples from different storage conditions from a
single lot), automated, overnight runs often are performed for better lab efficiency. Such
practices add requirements for greater solution stability.
     Samples and standards should be tested during a period of at least 24 h (depending on
intended use), and component quantification should be determined by comparison with
freshly prepared standards. For the assay method, the sample solutions, standard solutions
and HPLC mobile phase should be stable for  24 h under  defined storage conditions.
Acceptable stability is <2% change in standard or sample response, relative to freshly
prepared standards. The mobile phase is considered to have acceptable stability if aged
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mobile phase produces equivalent chromatography (capacity factors, resolution or tailing
factor) and the assay results are within 2% of the value obtained with fresh mobile phase.
1.6 FORCED DEGRADATION STUDIES
Forced  degradation  or  stress  testing  is  undertaken  to  demonstrate  specificity  when
developing stability-indicating methods, particularly when little information is available
about potential degradation products. These studies also provide information about the
degradation pathways and degradation products that could form during storage. Forced
degradation studies may help facilitate pharmaceutical development as well in areas such
as  formulation  development,  manufacturing,  and  packaging,  in  which  knowledge  of
chemical behavior can be used to improve a drug product(2).
EXPERIMENTAL APPROACH TOOLS:
Forced degradation studies of Active Pharmaceutical Ingredient (API) and Drug Product
(DP) include appropriate solid state and solution state stress conditions (like acidic/base
hydrolysis, heat, oxidation and light exposure) in accordance with ICH guidelines. Forced
degradation  studies  should  be  conducted  whenever  a  stability  indicating  method  is
required. Studies may need to be repeated as methods, processes, or formulations change.
The specified stress conditions should result in approximately 5-20% degradation of the
API or represent a reasonable maximum condition achievable for the API. The stressed
sample should be compared to the unstressed sample (control) and the appropriate blank.
A compound may not  necessarily degrade under  a  given stress condition.  No further
stressing is advised in these cases 
1. ACID:
     Typical acids include HCl or H2SO4 (0.1-1 mol/L solution).Studies should be carried
out in the solution state. For certain APIs that are partially soluble or insoluble in the
described acidic solution,addition of an appropriate co-solvent, or adjustment of solution
pH in the acidic range may be required to achieve dissolution, or the APIs can be run as
suspensions.Special  attention  to  the  API structure  should  be  paid  when  choosing the
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appropriate  co-solvent  (i.e.  do  not  use  alcohols  for  acidic  conditions  due  to  their
reactivity).Dimethylsulfoxide  (DMSO),  acetic  acid  and  propionic  acid  are  useful  for
acidic  conditions.  Additionally,  the  sample  may  be  heated  for  a  defined  time  and
temperature to accelerate degradation, depending on the API sensitivity to heat.
2. BASE:
     Typical bases include NaOH, LiOH, or KOH (0.1- 1 mol/L). Studies should be carried
out in the solution state. For certain API which are partially soluble or insoluble in the
described basic solution, addition of an appropriate co-solvent, or adjustment of solution
pH may be  required  to  achieve  dissolution,  or  the  APIs  can  be  run  as  suspensions.
Additionally, the sample may be heated for a defined time and temperature to accelerate
degradation depending on the API sensitivity to heat.
3. OXIDATION:
     Oxidation can be carried out under  an oxygen atmosphere or  in the presence of
peroxides. The use of oxygen is a more realistic model. Free radical initiator and peroxide
will  produce  a  primary  oxidation,  degradation  products  are  observed  on  real-time
stability. Therefore, free radical and/ or hydrogen peroxide condition based degradation
are  strongly  recommended  at  all  stages  of  development.  For  solution  state  stress
conditions, dissolve the API utilizing an appropriate solvent, add 5-20 mol% of a free
radical  initiator  at  atmospheric  pressure.  To  increase  the  solubility  of  oxygen  in  the
solution, the reaction can be performed in a reaction vessel  pressurized at 50-300 psi
(pound per square inch) with  molecular oxygen. Additionally the system is heated to
accelerate degradation. The temperature depends on the free radical initiator selected. For
peroxide conditions, hydrogen peroxide reagent (up to 3%) can be used. As previously
indicated, the addition of an appropriate co-solvent may be necessary, depending on API
solubility. Hydrogen peroxide stress testing can be useful in DP studies where hydrogen
peroxide is an impurity in excepients. Solid- state stress conditions may be similarity
investigated  by  placing  the  API  in  suitable  closed  containers  filled  with  an  oxygen
headspace  versus  argon  or  nitrogen  control  headspace.  Further,  light  can  also  affect
oxidation reactions, light absorbed by a photo sensitizer can react with molecular oxygen
to form the more reactive singlet oxygen species.
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4. THERMAL/HUMIDITY
Solid state stability can be evaluated utilizing accelerated storage temperatures in general
greater than 50°C and not more than 5% relative humidity(8). The duration of exposure is
dependent on the API sensitivity. If the forced degradation thermal/humidity conditions
produce  a  phase  change,  it  is  recommended  to  also  run  thermal/humidity  conditions
below the critical thermal/humidity that produces the phase change. Arrhenius kinetics
may be used to establish an appropriate temperature and maximum duration of thermal
degradation studies. Deviation from Arrhenius kinetics(9) is increasingly expected above
70-80°C, and the impact of this should be considered during experimental design.Using
an  appropriate  assumption  of  activation  energy,  the  duration  of  controlled  room
temperatures  storage  that  is  simulated  by the  study can  be  estimated.  In  general,  an
activation energy assumption of 15kcal/mol is recommended.
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2.1OBJECTIVE: 
• To develop an accurate, precise, linear, robust, simple and rapidstability indicating
HPLC   method for the determination of linagliptin.
• Validation  of  the  proposed  newly  developed  method  in  accordance  with  the
analytical parameters mentioned in the ICH guidelines.
• To apply the newly developed method for analysis of the linagliptin in their bulk
and pharmaceutical dosage form.
• To perform stress degradation studies for linagliptin.
2.2 SCOPE:
This study makes an attempt to establish sensitive and accurate method for estimation of
anti-diabetic  drug linagliptinin  pharmaceutical  dosage  form.To date  there  is  no  study
related to stability indicating HPLC method for determination of linagliptin reported in
literature up to our knowledge. Hence there is strong need to develop stability indicating
HPLC  method  for  determination  of  linagliptin.  By  performing  this  study,
reactivechemistry of linagliptin will be known. It is useful to anticipate future stability
issues of both drug substance and drug product by performing forced degradation studies
in acid, alkali, heat and oxidation. This study provides useful information for formulation
and stability.
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2.3PLAN OF WORK:
1. Carry out preliminary studies of linagliptin such as 
       a. Determination of melting point
b. Determination of λmax etc.,
2. Conducting initial chromatographic studies
3. Optimization of chromatographic conditions like
        a. Optimization of mobile phase
        b. Optimization of column
        c. Optimization of detection method.
d. Optimization of flow rate etc.,
4. Estimating validation parameters for optimized methods according to guidelines stated
inICH. 
Typical validation parameters are
a. Accuracy
b. Precision
c. Specificity
d. Linearity
e. Range
f. LOD
g. LOQ
h. Robustness
5. Performing the induced degradation studies under different stress conditions
       a. Acidic hydrolysis
       b. Basic hydrolysis
       c. Thermal degradation 
       d. Oxidative degradation etc.,
The Determination of Linagliptin Using HPLC Method..
Literature review
2.4LITERATURE REVIEW
1.  Lakshmi  B  et  al., reported  on  linagliptin  determination  by  simple,  precise  and
accurate RP-HPLC method and validated for assay of linagliptin in tablet dosage form.
Isocratic elution at a flow rate of 1.0 mL/min was employed on a symmetry Chromosil
C18 column (250x4.6mm, 5µm) at ambient temperature. The mobile phase consisted of
acetonitrile:  water:  methanol (25:50:25),  detection wavelength was 238 nm and 20µL
sample  was  injected.  The  retention  time  for  linagliptin  was  7  min  and  method  was
validated as per the ICH guidelines (1)
2. Archana M et  al., developed  a validated and novel isocratic  reverse phase liquid
chromatography method for determination of linagliptin. The chromatographic column
conditions employed were Khromosil C18 (150×4.6 mm, 5µm), mobile phase containing
0.02 M potassium dihydrogen phosphate: acetonitrile (70:30, v/v, pH 5.0 adjusted with
1% OPA solution) flow rate was 1.2 mL/min and effluents were monitored at 226 nm.(4)
3.Ramzia I,  et al.,developed a reversed-phase liquid chromatographic method for the
determination of linagliptin based on isocratic elution using a mobile phase consisting of
potassium dihydrogen phosphate buffer pH 4.6 - acetonitrile (20:80) at a flow rate of 1
mL/min,  with  cyanide  symmetry  column  (150  x  4.6  mm,  5µm).  Two  detection
techniques  have  been  applied  either  UV detection  at  299  nm in  the  first  method  or
fluorometric detection at 239 nm for excitation and 355 nm for emission in the second
method.  Linearity,  accuracy  and  precision  were  found  to  be  acceptable  over  the
concentration  ranges  of  2.5-80  µg/mL  for  linagliptin  in  bulk  and  2.5-15  µg/mL for
linagliptin in plasma with the first method and 5-160 µg/mL for linagliptin in bulk with
the second method.(3)
4.  LakshmanRaju  B,  et  al., developed  a  HPLC  method  for  the  determination  of
linagliptin  in  pharmaceutical  formulations,  including the  separation  of  impurities  and
excipients has been developed and validated. Isocratic elution at a flow rate of 1mL/ min
was employed on a symmetry C18column at  ambient temperature.  The mobile phase
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consisted of methanol: water 83:17(v/v) and pH of the mobile phase was adjusted to 4.1
with 0.1% orthophosphoricAcid . The UV detection wavelength was at 241nm, linearity
was observed in concentration range of 5-30 µg/mL and retention time for linagliptin was
5.85min and method was validated as per the ICH guidelines.(5)
5.DilipPatil A et al.,developed a rapid, sensitive and economical high performance liquid
chromatographic method for determination of linagliptin.  The chromatography system
containing reverse phase C18 column (250×4.6mm, 5µm) with a mixture of methanol:
water in a ratio of 40:60 and flow rate of 1.0 mL/min. Orthophosphoric Acid was used as
buffer to maintain the pH 3 of mobile phase. UV detector was used at 238 nm and 20µL
sample was injected. The method was validated as per ICH guidelines. The retention time
of linagliptin was found to be 7.3 min, calibration curve is linear in the range of 2-10
µg/mL. This study proved that the method can be successfully used for routine analysis
of linagliptin form tablets formulation(6).
6.Gallwitzt B et al., reported on 2-year efficacy and safety of linagliptin compared with
glimepiride  in  patients  with  type  2  diabetes  inadequately controlled on  metformin:  a
randomised,  double-blind,  non-inferiority  trial.  This  study  includes  comparsion  of  a
dipeptidyl  peptidase-4  inhibitor  (linagliptin)  against  a  commonly  used  sulphonylurea
(glimepiride).  This  study  utilizes  parallel-group,  non-inferiority  double-blind  trial,
conducted on outpatients with type 2 diabetes and glycatedhaemoglobinA(1c) (HbA(1c))
(37)6·5-10·0%.  Glimipride  and  metformin  combination  was  given  initially  and  then
linagliptin and metformin was given. Then (HbA(1c)) levels decreased with metformin
and linagliptin. The findings could improve decision making for clinical treatment when
metformin alone is insufficient.(10)
7.  Thomas H,reported on initial combination with linagliptin and metformin in newly
diagnosed  type  2  diabetes  and  severe  hyperglycemia.  This  phase  3  study,  open-label
treatment  of  severely  hyperglycemic  patients  (HbA1c  ≥11.0%)  with  linagliptin  plus
metformin resulted in a mean change in HbA1c of −3.7% ± 1.7%. Combination therapy
was  generally  well  tolerated  with  most  adverse  events  being  of  mild  or  moderate
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intensity.  Asymptomatic  hypoglycemia  was  reported  by just  1  of  66 (1.5%) patients.
These  findings  provide  evidence  in  support  of  linagliptin  plus  metformin  as  a  well-
tolerated and effective treatment alternative to insulin for new-onset patients with type 2
diabetic mellitus (T2DM) and severe hyperglycemia. 
8. Kavitha. K. Y, developed a simple, RP-HPLC method was established for determining
linagliptin  and  metformin  in  pharmaceuticalformulations.  Linagliptin  and  metformin
degradation products were separated using C8 column withacetonitrile: water: methanol
(25:50:25 (v/v/v), pH of the mobile phase was adjusted to 4.1 with 0.1% orthophosphoric
acid.Detection was performed at 243 nm using a diode array detector. The method was
validated using ICH guidelinesand was linear in the range 5-30µg/mL and 10-100 µg /mL
for linagliptin and metformin respectivily. Good separationof both the analytes and their
degradation products was achieved using this method.(12).
9.Christian  F  et  al., conducted  a  study  to  investigate  the  pharmacokinetics  of
empagliflozin and linagliptin after co-administration to healthy volunteers. In this study
sixteen healthy male subjects received treatment A (empagliflozin 50 mg once daily for 5
days), treatment B (empagliflozin 50 mg once daily and linagliptin 5 mg once daily for 7
days),  treatment  C (linagliptin 5  mg once daily for  7  days)  sequence AB then C, or
sequence  C  then  AB.  No  adverse  events  were  reported  during  the  co-administration
period  and  no  hypoglycemia  was  reported.  Empagliflozin  and  linagliptin  were  well
tolerated.  These  data  support  the  co-administration  of  empagliflozin  and  linagliptin
without dose adjustments.
10. Ranjit S et al., reported current trends in forced degradation study for pharmaceutical
product development. This study explains that forced degradation is a powerful tool used
routinely in pharmaceutical development in order to develop stability indicating methods
that lead to quality stability data and to understand the degradation pathways of the drug
substances  and  drug  products.  Study  describes  the  mechanism  of  formation  and
characterization  of  generated  impurities  during  force  degradation  studies  in
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pharmaceuticals.  Force  degradation  studies  ensure  appropriate  stability  of  final
pharmaceutical product in very early stages of pharmaceutical development.(31)
11. George N et al., reported on force degradation studies, explained that HPLC method
should be able to separate, detect and quantify the various drug related degradants that
can form on storage or manufacturing and quantify any drug related impurities that may
be introduce during synthesis. Further, described the general degradation procedure in
different conditions like photolytic,  thermal,  acidic,  basic and oxidative conditions. In
general, a target of approximately 10% degradation of API during force degradation or
exposure to energy in slight excess of what is typically used in accelerated storage is
recommended.
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2.5 DRUG PROFILE
DRUG NAME:Linagliptin
IUPAC  NAME:   8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-  methyl-1-[(4-
methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione.
CHEMICAL FORMULA:  C25H28N8O2
MOLECULAR WEIGHT: 472.54g/mol
TRADE NAMES:Tradjenta, Trajenta
STRUCURE:     
PHYSICAL STATE: Yellowish white amorphous powder
NATURE: Slightly hygroscopic
pKa : pKa1= 8.6 ; pKa2 = 1.9
PARTITION COEFFICIENT:   logP = 1.7 (free base)
logD (pH 7.4) = 0.4
SOLUBILITY: 
• Slightly soluble in water.
• Soluble in methanol.
• Sparingly soluble in ethanol.
• Very slightly soluble in isoproponol.
• Very slightly soluble in acetone. 
BIOAVAILABILITY:  30%.
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PROTEIN BINDING:Plasma protein binding of linagliptin is concentration-dependent,
decreasing from about 99% at 1 nmol/L to 75%-89% at ≥30 nmol/L, reflecting saturation
of  binding  to  dipeptidyl  peptidase-4  with  increasing  concentration  of  linagliptin.  At
highconcentrations,  where  dipeptidyl  peptidase-4  is  fully  saturated,  70%  to  80%  of
linagliptin remains bound to plasma proteins and 20% to 30% is unbound in plasma.
Plasma binding is not altered in patients withrenal or hepatic impairment.
METABOLISM:  In  oral  administration,  the  majority  (about  90%)  of  linagliptin  is
excreted unchanged, indicating that metabolism represents a minor elimination pathway.
Asmall  fraction of  absorbed  linagliptinis  metabolized to  a  pharmacologically inactive
metabolite, which shows a steady-state exposure of 13.3% relative to linagliptin.
EXCRETION: In oral [14C]-linagliptin dose to healthy subjects, approximately 85% of
the administered radioactivity was eliminated via the enterohepatic system (80%) or urine
(5%) within 4  days  of  dosing.  Renal  clearance at  steady state  was approximately 70
mL/min.
MECHANISM OF ACTION:Linagliptin is a dipeptidyl peptidase-4 inhibitor developed
by BoehringerIngelheim  (German  Pharmaceutical  Company)  for  treatment  of  type  II
diabetes(7).  It  was approved by the US FDA on 2 May 2011 for treatment  of  type II
diabetes..  DPP-4(dipeptidyl  peptidase  4)  is  an  enzyme  that  degrades  the  incretion
hormones,  glucagon  like  peptide-1  (GLP-1)  and  glucose-  dependent  insulinotropic
polypeptide (GIP). Both GLP-1 and GIP increase insulin biosynthesis and secretion from
pancreatic beta cells in the presence of normal and elevated blood glucose levels. GLP-1
also reduces glucagon secretion from pancreatic alpha cells, resulting in a reduction in
hepatic glucose output. Thus, linagliptin stimulates the release of insulin in a glucose-
dependent manner and decreases the levels of glucagon in the circulation, and showed
that the drug can effectively reduce blood sugar.
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3.1. MATERIALS AND METHODS 
Linagliptinwas  a  generous  gift  sample  from  Crystal  marphix  Pvt  Ltd,  Hyderabad.
Formulation  product  Trajenta  tablets  (labeled  as  5mg  of  linagliptin  per  tablet)  were
supplied  by  Boehringer  Ingelheim  India.  HPLC  grade  methanol  and  acetonitrile,
analytical  grade  potassium  dihydrogen  phosphate,  orthophosphoric  acid  and
triethylamine,  laboratory  reagent  grade  hydrochloric  acid,  sodium  hydroxide  and
hydrogen  peroxide  were  purchased  from Merck,  India.   Water  was  purified  through
Direct-Q 3 UV water purification system (Merck Millipore, India) 
INSTRUMENTS:
Name of the instrument Make
Sonicator Analytical Technologied ltd
Cyclo mixer Remi
Weighing balance Sartorious balance
HPLC instrument (manual) Analytical Technologies ltd P2230 with A-2000
software and version 1.6.
HPLC column:     MicrosorbC-8 column (150
mm  x 4.6 mm, 5 µm)
Ranin instrument company, USA
pH meter Systronics
3.1.1. PRELIMINARY STUDY
3.1.2. DETERMINATION OF MAXIMUM WAVELENGTH (λmax)OF 
ABSORPTION OF LINAGLIPTIN:
     Maximum wavelength (λmax)of linagliptin(38) was established by scanning the drug
solution in UV. From the stock solution (1mg/mL)200µl of sample is diluted to 10ml with
methanol to obtain 20µg/ml solution and scanned in UV region. 
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3.1.3. DETERMINATION OF LINEARITY IN UV:
Linearity was established by least squares linear regression analysis of the calibration
curve. The constructed calibration curve was linear over concentration range of 2 µg/ml
to 25µg/ml at 295nm and 0.8 µg/ml to 8 µg/ml at 225nm. 
3.1.4. HPLC INSTRUMENTATION AND CONDITIONS:
     The HPLC system consisted of Analytical technology model 2230 equipped with   UV
detector and data collection as well as analysis were carried out through A2000 software.
The elution was performed with following conditions
Flow rate   :     1.0 mL/min
Column        :     MicrosorbC8 column (150 mm  x 4.6 mm, 5 µm) 
Mobile phase :     40 mM phosphate buffer (pH 3), and acetonitrile (70:30,v/v)
Detector wavelength     :     225 nm
Column temperature      :     Ambient temperature
Injection volume            :     20 µL
Run time             :    10 min 
3.1.5. BUFFER PREPARATION:
     5.4436gm of potassium dihydrogen phosphate was dissolved in HPLC water and
transferred to 1000 mL volumetric flask, volume was made up to 1000ml with HPLC
water, pH  of the solution  adjusted to  3 with ortho phosphoric acid. Then buffer was
filtered through 0.45 µm filter.
3.1.6. PREPARATION OF STANDARD STOCK SOLUTION
Standard  stock  solution  of  linagliptin  (1000µg/mL)  was  prepared  in  methanol  by
dissolving  50mg  of  linagliptin  in  50  mL of  methanol.  The  required  concentrations
prepared by serial dilutions of the stock solution. 
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3.1.7.SAMPLE PREPARATION
Ten tablets were weighed, their mean weight was determined, and crushed in a mortar.
An amount of powdered mass equivalent  to one tablet  content was transferred into a
50mL volumetric flask.To it add 10mL of methanol and mechanically shaken for 10min,
ultra sonicated for 5min and make up to the volume up to 50mL with methanol. From this
1mL is taken then diluted with mobile phase up to 10mL, filtered through 0.2µm nylon
filter.
3.1.8. METHOD VALIDATION(33)
3.1.8.1. SYSTEM SUITABILITY
     System suitability was determined from six replicate injections of standard preparation
(10 µg/mL), which was prepared from appropriately diluting standard stock solution. All
important  characteristics  including retention  time,  tailing factor,  capacity factor,  peak
resolution, and theoretical plate number were analyzed. 
Acceptance criteria
1. The % RSD (relative standard deviation) for  the retention times of linagliptin
peak from 6 replicate injections of each standard solution should be not more than
2.0%.
2. The number of theoretical plates (N) for linagliptin peaks should be not less than
2000.
3. The tailing factor (T) for linagliptin the peaks should be not more than 2.0.
3.1.9. LINEARITY
Accurately measured aliquots of standard stock solution contacting 2-160 µg of linaglptin
were transferred into 10 mL volumetric flasks in triplicate and volume was made up to 10
mL with mobile  phase.  Each solution was analyzed by injecting 20µL volume.   The
calibration curve was obtained by plotting peak area against concentration. Further the
linearity(34) was  evaluated  by  the  determination  of  standard  deviation  (SD),  slope,
intercept and correlation coefficient (r2). 
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Acceptance criteria 
1. Correlation coefficient should be not less than 0.999.
2. % RSD of peak areas for solutions should not be more than 2.0%.
3.1.10.  LIMIT  OF DETECTION  (LOD)  AND  LIMIT  OF QUANTIFICATION
(LOQ)
Limit  of  detection  (LOD)  and  Limit  of  quantification  (LOQ)  were  determined  based  on  the
standard deviation of the response and the slope. The standard deviation of the response and
the slope of the calibration curve were calculated from the slope and y-intercept of the mean
equation of three calibration curves(43).
The limit of detection was calculated by using the formula
                           LOD  = 3.3   σ 
S 
where 
σ = the standard deviation of the response 
S = the slope of the calibration curve 
The limit of quantification was calculated by using the formula
                             LOQ = 10   σ 
                                           S 
where 
           σ = the standard deviation of the response 
           S = the slope of the calibration curve.
3.1.11. SPECIFICITY
The specificity(36) of the HPLC method was determined by the complete separation of 
linagliptin along with other parameters like retention time (RT), capacity factor (k), 
tailing or asymmetrical factor (T), etc. 
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Acceptance criteria 
1. Chromatogram of  standard and sample should be identical  with near retention
time.
2. Chromatogram of blank should not show any peak at the retention time of analyte 
peak.
     There is no interference due to blank at the retention time of analyte. Hence the 
method is specific.
3.1.12. PRECISION
The repeatability of the proposed HPLC method was assessed by three replicate injection
of three different concentrations (6, 10 and 14 µg/mL) of linagliptin, representing 60,
100, 140%, respectively(42). The experiments described in repeatability were repeated for
three consecutive days to establish intermediate precision.
Acceptance criteria
1. % RSD of peak areas should not be more than 2.0%.
2.1.13. ACCURACY
To establish  accuracy,  recovery  studies  were  carried  out  by spiking  known  standard
samples into sample solution. Known amount of the standards at 80,100 and 120% levels
were  fortified  to  sample  solution.  Peak  areas  of  standards  were  calculated  by  the
difference  of  peak  areas  between  fortified  and  unfortified  sample(22).  Three  replicate
samples of each concentration level were prepared and the recovery at each level (n = 3),
and mean recovery (n = 9) were determined. The percentage recoveries were calculated
from the slope and y-intercept of the calibration curve(39).
Acceptance criteria
1. The mean % recovery of linagliptin at each spike level should be not less than
98.0% and not more than 102.0%.
3.1.14. ROBUSTNESS
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     The robustness of the method was evaluated through the studies of influence of small
and  premeditated  alteration of  analytical  parameters(23).  The parameters  selected were
flow rate (±10%) mobile phase composition (acetonitrile ±3%), pH of the buffer (±7%)
and buffer concentration (±12%). Only one parameter was altered while the remaining
parameters were kept constant. 
Effect of variation flow rate
A study was conducted  to  determine  the  effect  of  variation  in  flow rate(40).  Standard
solution  was  prepared  and  injected  in  to  the  HPLC  system  by  keeping  flow  rates
0.9mL/min and 1.1mL/min. The effect of variation of flow rate was evaluated.
Acceptance criteria
1. The %RSD of tailing factor and retention times of linagliptin standard should not
be more than 2.0.
Effect of variation of mobile phase composition
A study was conducted to determine  the effect  of  variation in  mobile  phase ratio  by
changing the ratio of mobile phase(41) i.e., acetonitrile ±3% (v/v), standard solution was
prepared and injected in to the HPLC system. The effect of variation of mobile phase was
evaluated.
Acceptance criteria
2. The %RSD of tailing factor and retention times of linagliptin standard should not
be more than 2.0 variations in composition of mobile phase.
Effect of variation of pH
A study was conducted to determine the effect of variation in pH by changing the pH of
buffer(45)i.e. ±7%. Standard solution was prepared and injected into the HPLC system.
The effect of variation of pH was evaluated.
1. The tailing factor of linagliptin standard should not be more than 2.0 for variation
in pH.
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2. The %RSD of asymmetry and retention time of linagliptin standard should be not
more than 2.0% for variation in pH.(48)
Effect of variation in Buffer concentration
A study was conducted to determine the effect of variation in buffer concentration by
changing the buffer concentration(44) i.e.  ± 12% . Standard solution was prepared and
injected into HPLC system. The effect of variation of buffer concentration was evaluated.
Acceptance criteria
1. The tailing factor of linagliptin standard should not be more than 2.0 for variation
in buffer concentration(47).
2. The %RSD of asymmetry and retention time of linagliptin standard should be not
more than 2.0% for variation in buffer concentration.
3.1.15. FORCED DEGRADATION STUDIES(32)
HYDROGEN PEROXIDE INDUCED DEGRADATION
The standard stock solution (0.1mL) of  was transferred into 10 mL volumetric flask,
added with 3 mL of  3% hydrogen peroxide solution  The solution was kept at room
temperature  for  3  hours  and  diluted  to  10mL with  mobile  phase.  The  20  µL of  the
resultant solution was injected and analysed.
THERMAL DEGRADATION
The 10 mg of linagliptin API was transferred into a clean 10mL volumetric flask, placed
in oven at 60˚C for 10 days to evaluate dry heat degradation. After 10 days dissolved and
volume was made up with methanol.  Further serial dilutions were made with mobile
phase to attain 10 µg/Mlconcentration, 20 µL of the resultant solution was injected and
analysed.
ACID INDUCED DEGRADATION
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To 0.1 mL of linagliptin stock solution in different 10 mL volumetric flasks, 3 mL of
either 0.1N or 1N hydrochloric acid was added, separately.  The mixtures were kept at
room temperature  for  3  hr,  24  hr  and 48 hr  duration(49),  neutralized with  appropriate
amount of either 0.1N or 1N sodium hydroxide solution or volume was made up to 10
mL with mobile phase.  The similar experiments repeated at higher temperature of 60˚C
for 3 hr duration. The 20 µL of the resultant solution was injected and analysed.
BASE INDUCED DEGRADATION
To 0.1 mL of linagliptin stock solution in different 10 mL volumetric flasks, 3 mL of
either 0.1N or 1N sodium hydroxide solution was added, separately.  The mixtures were
kept at room temperature for 3 hr, 24 hr and 48 hr duration, neutralized with appropriate
amount of either 0.1N or 1N hydrochloric acid or volume was made up to 10 mL with
mobile phase.  The similar experiments repeated at higher temperature of 60˚C for 3 hr
duration. The 20 µL of the resultant solution was injected and analysed.(50)
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4. RESULTS
4.1. PRELIMINARY STUDY
4.1.1. DETERMINATION OF MAXIMUM WAVELENGTH OF 
ABSORPTION(λmax) OF LINAGLIPTIN:
Figure: 4.1. Scan spectra of linagliptin
4.1.2. DETERMINATION OF LINEARITY IN UV
Table No 4.1.  Results of calibration curve at 295nm in UV
Concentration Absorbance at 295nm
2 0.079
5 0.193
8 0.29
10 0.421
12 0.487
15 0.676
20 0.803
25 1.054
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Figure:4.2. Calibration curve in UV at 295nm
Table No 4.2. Results of calibration curve at 225nm in UV
concentration Absorbance at 225nm
0.8 0.129
1 0.146
2 0.259
3 0.428
4 0.51
5 0.658
6 0.756
7 0.921
8 0.996
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Figure: 4.3 Calibration curve in UV at 225nm
 OPTIMIZED METHOD
The Determination of Linagliptin Using HPLC Method. Page 
Results
[Minutes]
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
-10
42
94
146
198
250
300
[
m
v
]
1
 
 
Figure: 4.4. A typical chromatogram of 20µL injection of linagliptin standard
solution (10µg/mL) 
Peak area Tailing factor Retention time Theoretical plates
1289 1.56 4.17 23045
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Figure: 4.5. A typical chromatogram of blank
 METHOD VALIDATION
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Table No 4.3. System suitability parameters
Property Mean ± SD ( n=6) % RSD Required limits
Retention time 4.19 ± 0.03 0.71 ≤ 2%
Capacity factor 2.30 ± 0.002 0.087 2-5
Theoretical plates 22364 ± 198 0.88 > 2000
Tailing factor 1.52 ± 0.004 0.26 ≤ 2
LINEARITY
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Figure: 4.6. Overlay of the chromatograms of linagliptin solutions (0.2 – 16 µg/mL
concentration)
Table No: 4.4.Calibration curve data of linagliptin
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Concentratio
n
(µg/mL)
Mean peak area ±
SD
Tailing factor Retention time
(min)
Theoretical
plates/meter
0.2 22.323± 0.288675 1.58 4.24 22279
0.5 74.466± 0.321438 1.61 4.21 21798
1 155.559± 0.404145 1.57 4.22 22834
6 791.666± 2.516611 1.59 4.19 21710
8 1031.333 ±
6.506407
1.59 4.24 22771
10 1286.667 ±
4.932883
1.62 4.25 22833
12 1520.667 ± 7.371115 1.62 4.25 22578
14 1792.333 ± 3.511885 1.65 4.26 22691
16 2014.333 ± 4.50925 1.63 4.26 23547
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Figure: 4.7. Calibration curve of linagliptin
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LOD AND LOQ
 LOD = 3.3 X σ / S
       σ = the standard deviation of the response = 0.3162
S = the slope of the calibration curve = 125.93
                       LOD = (3.3 X 0.3162) / 125.93
                                = 0.008µg/mL
LOQ = 10 X σ / S
                             σ = the standard deviation of the response = 0.3162
                             S = the slope of the calibration curve = 125.93
                                = (10 X 0.3162) / 125.93
                                = 0.025 µg/mL  
Table No 4.5 LOD and LOQ of linagliptin
LOD(µg/mL) LOQ(µg/mL)
0.008 0.025
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ACCURACY
Table No: 4.6. Recovery studies of lingliptin spiked with formulation by standard
addition method.
Concentratio
n
(%)
Volume of
standard
solution
(100µg/mL)
(mL)
Volume of
spiked
sample
solution
(100µg/mL)
(mL)
Total
concentration
obtained
Concentrati
on
calculated,
±SD, %
RSD
%
recovery
80% 0.8mL 1 mL 18µg/mL 18.33±0.21,
0.73
101.83%
100% 1mL 1mL 20µg/mL 20.34±0.17,
0.42
101.52%
120% 1.2mL 1mL 22µg/mL 22.07±0.51,
1.02
100.31%
SPECIFICITY
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Figure: 4.8. A typical chromatogram of 20µL injection of linagliptin standard
solution (10µg/mL) 
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Figure: 4.9. A typical chromatogram of blank
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PRECISION
SYSTEM PRECISION
Table No: 4.7.  Results of system precision
Concentration
(µg/ml)
Intraday precision Inter day precision
Mean peak area ± SD,
% RSD,(n=6)
Mean retention  time ± SD,
% RSD (n=6)
Mean peak area ± SD, %
RSD,(n=18)
Mean  retention   time  ±
SD, % RSD (n=18)
10 1295 ± 18.81, 1.45 4.18 ± 0.0008, 0.19 1261 ± 16.69, 1.32 4.22 ± 0.03, 0.787
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METHOD PRECISION
Table No 4.8. Results of method precision
Concentration
(µg/ml)
Intraday precision Inter day precision
Mean peak area ± SD, %
RSD,(n=3)
Mean retention  time ±
SD, % RSD (n=3)
Mean peak area ± SD, %
RSD,(n=9)
Mean retention  time ±
SD, % RSD (n=9)
6 796.66 ± 0.015, 1.56 4.24  ±  0.005 , 0.13 801 ± 0.133, 1.17 4.24 ± 0.0051, 0.121
10 1289 ± 0.051, 0.50 4.26 ±  0.025, 0.59 1283.11 ±  0.06677, 0.66 4.26 ± 0.022, 0.527
14 1770 ± 0.049, 0.35 4.24 ±  0.02, 0.49 1770.66± 0.067, 0.48 4.24 ± 0.0150, 0.354
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ASSAY OF LINALIPTIN IN MARKETED FORMULATION
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Figure: 4.10.  Chromatogram of assay of linagliptin in marketed formulation Trajenta
Table No 4.9. Results of assay of linagliptin
Brand name Labeled amount (mg) Calculated concentration
(mg) ± SD (N = 3)
Assay %
Trajenta 5 5.05 101%
y = 125.8x + 17.58
x = (y - 10.102)/125.8 = 10.102
Results
ROBUSTNESS
Table No: 4.10.  Results of robustness
VARIABLE
FACTOR
LEVEL RETENTION TIME TAILING FACTOR PEAK AREA
Change in flow
rate
Decreased flow rate (0.9mL/min) 4.76 1.40 1234
Nominal flow rate (1mL/min) 4.49 1.42 1261
Increased flow rate(1.1mL/min) 4.18 1.42 1195
Change in ACN
composition
DecreasedACN concentration (29%) 4.99 1.41 1199
Nominal ACN concentration(30%) 4.49 1.42 1260
Increased ACN concentration(31%) 4.08 1.42 1206
Change in buffer
pH
Decreased buffer (pH 2.8) 4.43 1.42 1210
Nominal buffer (pH 3) 4.49 1.42 1260
Increasedbuffer (pH 3.2) 4.54 1.42 1221
Change in buffer
concentration 
Decreasedbuffer concentration (35mM) 4.51 1.43 1243
Nominal buffer concentration(40mM) 4.49 1.42 1261
Increased buffer concentration(45mM) 4.41 1.41 1224
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SOLUTION STABILITY
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Figure: 4.11.  Chromatogram indicating solution stability of linagliptin (1hr) 
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Results
Time Peak area
0 1284
15min 1297
30min 1262
1hr 1291
2hr 1282
3hr 1290
24hr 1289
Mean ± SD 1284.33 ± 12.17
 % RSD 0.98
FORCED DEGRADATION STUDIES
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Figure: 4.13.Standard chromatogram of linagliptin (10µg/mL) for comparing degradation
samples
Peak area Tailing factor Retention time Theoretical plates
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Figure: 4.14 Chromatogram of dry heat degraded linagliptin
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Figure: 4.16Chromatogram of linagliptin degraded with 3% H2O2
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Figure: 4.17. Overlapping chromatograms in 3% H2O2 and standard linagliptin
ACID INDUCED DEGRADATION
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Figure: 4.19. Overlapping chromatograms of linagliptin treated with 0.1N HCl at room
temperature for 3 hours and standard linagliptin.
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Figure: 4.21. Overlapping chromatogram of linagliptin treated with 0.1N HCl at 60oC for 3
hours and standard linagliptin.
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Figure: 4.23. Overlapping chromatograms of linagliptin treated with 1N HClat room
temperature for 3 hours and standard linagliptin.
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Figure: 4.25. Overlapping chromatograms of linagliptin treated with 1N HCl at 60oC for 3
hours and standard linagliptin.
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Figure: 4.27. Overlapping chromatograms of linagliptin treated with 0.1N HCl at 60oC for
24 hours and standard linagliptin
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Figure: 4.28.Chromatogram of linagliptin treated with 1N HCl  at room temperature for 24
hours
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Figure: 4.29. Overlapping chromatogram of linagliptin treated with 1N HCl at 60oC for 24
hours and standard linagliptin
BASE INDUCED DEGRADATION
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Figure: 4.30. Chromatogram of linagliptin treated with 0.1N NaOH at room temperature
for 3hours
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Figure: 4.32. Chromatogram of linagliptin treated with 1N NaOH at room temperature for
3hours
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Figure: 4.34.Chromatogram of linagliptin treated with 0.1N NaOH at 60oC for 3hours
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Figure:4.36. Chromatogram of linagliptin treated with 1N NaOH at 60oC for 3hours
Peak area Tailing factor Retention time Theoretical plates
59.79 1.21 4.31 226345
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Figure: 4.38.Chromatogram of linagliptin treated with 0.1N NaOH at room temperature
for 24hours.
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Table No 4.12. Resultsof linagliptin treated with 1N NaOH at 60oC at time intervals 0, 15,
30, 45, 60, 75, 90, 115min
0 20 40 60 80 100 120 140
0
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CONC
TIME Cocn
X = (Y-c)/m
0 8.622183
15 6.399781
30 3.471725
45 2.052308
60 1.614316
75 1.241212
90 0.934374
115 0.770776
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Figure: 4.41. Overlapping chromatogramsof linagliptin treated with 1N NaOH at 60oC at
time intervals 0, 15, 30, 45, 60, 75, 90, 115min
Table No 4.13. Resultsof linagliptin treated with 1N NaOH at 60oC at time intervals 0, 3,6,9,
12, 15, 18 min
TIME Cocn 
X = (Y-c)/m
0 8.143556
3 7.585846
6 7.421762
9 6.707997
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Figure: 4.42.Plot of Time vs Conc
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Summary
5. SUMMARY
PRELIMINARY STUDY
DETERMINATION OF MAXIMUM WAVELENGTH (λmax)OF DRUG:
     The maximum wavelength  of absorption (λmax) of linagliptin was established by
scanning the drug solution (20µg/ml) for UV absorption. The absorption spectra showed
two absorption  maxima,  at  225nm and  295nm.Further,  calibration  curve  obtained  by
plotting absorption versus concentration was linear at 225 nm in 0.8 -8 µg/mL range with
coefficient of determination of 0.996 and at 295 nm in 2-25µg/mL range with coefficient
of determination of 0.992.
From the aforementioned data, the 225 nm was found to be appropriate wavelength for
analysis. The data of scan spectra of linagliptin was shown in Fig: 3.1.
DETERMINATION OF LINEARITY IN UV:
Linearity was established by least squares linear regression analysis of the calibration
curve.  The  constructed calibration  curve  was  linear  over  concentration range  of  2  to
25µg/mL at 295nm and 0.8 to 8 µg/mL at 225nm. Absorbance of linagliptin was plotted
versus  their  respective  concentrations  and  linear  regression  analysis  on  the  resultant
curves.  Typically,  the regression equation was y = 0.042x – 0.016 at 295nm and y =
0.123x + 0.027 at 225nm. The data of linearity was illustrated in Table: 3.1 and Table:
3.2.
METHOD DEVOLOPMENT AND OPTIMIZATION 
The chromatographic method was optimized by changing various parameters such as pH
of  the  mobile  phase,  organic  modifier  and  composition  of  the  mobile  phase.  The
linagliptin UV absorption spectra revealed two absorption maxima at 225 nm and 295
nm. The response with wavelength 295 nm was low compared with 225 nm, which was
selected as detection wavelength for analysis. Initially mobile phase used was 30 mM
phosphate buffer (pH 3) and methanol (60:40, % v/v) gave bad peak shape, very less
theoretical  plates  and  retention  time  was  too  long.  To  improve  these  parameters,
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acetonitrile  was  introduced  into  mobile  phase,  30  mM  phosphate  buffer  (pH  3),
acetonitrile  and  methanol  (60:30:10,  % v/v)  employed  as  mobile  phase,  LC  analysis
indicated  broad  peak  shape  and  theoretical  plates  are  below the  acceptance  criteria.
Further methanol was eliminated from mobile phase, the binary solvent system consisting
30  mM  phosphate  buffer  (pH  5),  and  acetonitrile  (30:70,  %  v/v),  produced  no
improvement in theoretical plates count.  Further, theoretical plates were improved by
increasing buffer concentration to 40 mM and keeping the pH same but peak tailing was
more.Subsequently,pH of the buffer reduced to 3, approximately 1.1 units above pKa2 of
linagliptin,  acceptable  theoretical  plates  count  and  peak  tailing  factor  were  obtained,
probably due to less  ionization of linagliptin imparting decreased polar  contacts with
stationery phase.  Finally, using C8 (25 cms long 4.6mm inner diameter) column,  mobile
phase consisting of  40 mM phosphate buffer (pH 3), and acetonitrile (70:30, % v/v), at
flow rate 1 mL/min produced all system suitability parameters in acceptable range.
METHOD VALIDATION:
SYSTEM SUITABILITY
     System suitability tests are integral part of method development and are used to ensure
adequate performance of the chromatographic system. The parameters of these tests are
retention  time  (RT),  number  of  theoretical  plates  (N)  and  tailing  factor  (T),  were
evaluated for six replicate injections of the drug at concentration 10 µg/mL. Mean ±SD,
RSD (%) of retention time, capacity factor (k), theoretical plates (N) and tailing factor (T)
for linagliptin was found to be 4.19 ± 0.03, 2.30 ± 0.002, 22364 ± 198, 1.52 ± 0.004
respectively. The data system suitability was illustrated in Table: 3.3.
LINEARITY
Linearity was established by least squares linear regression analysis of the calibration
curve. Peak areas of linagliptin were plotted versus their respective concentrations and
linear regression analysis on the resultant curves. The constructed calibration curve was
linear over concentration range of 0.2 to 16 µg/ml. Typically, the regression equation was
y = 125.8x + 17.58, and correlation coefficient was 0.999, illustrates good linearity of
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calibration curve having high correlation coefficient. The data of linearity was illustrated
in Table: 3.4.,   and the linearity curve was plotted and given in Fig: 3.6.
ACCURACY
     Accuracy of the method was determined by performing the % recovery experiment.
Known amount of standard solution at 80, 100 and 120% levels were fortified to the
formulation solution.  Peak areas of standard were calculated by the difference of peak
areas  between  fortified  and  unfortified  samples.  Three  replicate  samples  of  each
concentration level were analysed and the % recovery at each level (n=3), and mean %
recovery (n=9). For, linagliptin the results obtained were in good agreement with label
claim. The results reported in Table 3.6.
SPECIFICITY:
     The specificity of the HPLC method was determined by the complete separation of
linagliptin  along  with  other  parameters  like  retention  time  (RT),  capacity  factor  (k),
tailing or  asymmetrical  factor  (T),  etc.  The results  obtained were shown in  Fig: 3.8.
andFig: 3.9.Mean retention time (min)  ±  SD for linagliptin of concentration 10µg/mL
was found to be 4.18 ± 0.0008, 0.19 respectively, for six replicates of standard solution.
The peaks obtained were sharp and have clear baseline separation. The chromatogram of
the pharmaceutical formulation indicated that no additional peaks and interference from
any excipients. In addition, degradation studies showed good resolution and devoid of
interference from any of the degraded products.
PRECISION
Method precision
The intra and inter-day variability or precision data and were assessed by using standard
solutions prepared to produce solutions of three different concentrations of drug (6, 10
and  14  µg/mL),  representing  60,  100,  140%  respectively.  Repeatability  or  intra-day
precision was investigated by injecting three replicate samples of each of the samples of
three different concentrations. Inter-day precision assessed by injecting the same three
concentrations  over  three  consecutive  days.  The  % RSD results  of  repeatability  and
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intermediate precision were within 2.0%; ascertaining good precision of the proposed
new method. The results were reported in Table: 3.8.
Intra-day precision
     Mean peak area (mv.sec) ± SD,%RSD for linagliptin of concentrations 6, 10 and 14
µg/mL are found to be  796.66 ± 0.015,1.56 ; 1289 ± 0.05, 0.50 and 1770 ± 0.049,0.35
respectively. Mean retention time ± SD,%RSD for linagliptin of concentrations 6, 10 and
14 µg/mL are found to be 4.24 ±  0.005 , 0.13; 4.26 ±  0.025, 0.59 and 4.24 ± 0.02, 0.49
respectively. The results were reported in Table: 3.8
Inter-day precision 
Mean peak area ± SD,RSD(%) for linagliptin of concentrations 6, 10, and 14 µg/mL are
found  to  be  801  ±  0.133,  1.17;  1283.11  ±  0.06677,  0.66and  1770.66±  0.067,  0.48
respectively. Mean retention time ± SD,%RSD for linagliptin of concentrations 6, 10 and
14 µg/mL are found to be  4.24 ± 0.005, 0.12; 4.26 ±  0.022, 0.527 and 4.24 ± 0.015,
0.354 respectively. The results were reported in Table: 3.8.
SYSTEM PRECISION
The intra and inter-day variability or precision data and were assessed by using standard
solution of concentration 10µg/mL. Repeatability or intra-day precision was investigated
by injecting 10µg/mL for six times within the same day. Inter-day precision assessed by
injecting 10µg/mL for six  times over three consecutive days. Both intraday precision and
interday precision of the new analytical method are found to be good based on %RSD,
corresponding to peak areas and retention times.
Intra-day precision
     Mean peak area (mv.sec) ± SD, % RSD for linagliptin of concentration 10µg/mL was
found to be 1295 ± 18.8, 1.45, mean retention time (min) ± SD, % RSD for linagliptin of
concentration 10µg/mL was found to be 4.18 ± 0.0008, 0.19. The results were reported in
Table: 3.7.
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Interday precision 
     Mean peak area (mv.sec) ± SD,  % RSD for linagliptin of concentration 10µg/mL was
found to be 1261 ±16.69, 1.32. Mean retention time (min) ± SD, % RSD for linagliptin of
concentration 10µg/mL was found to be 4.22 ± 0.03, 0.787respectively. The results were
reported in Table: 3.7.
SOLUTION STABILITY
The stability of linagliptin in mobile phase was investigated by analyzing the standard of
linagliptin (10µ/mL) at 0min, 15min, 30min, 1hr, 2hrs, 3hrs, 24hrs, after preparation at
room temperature.  No significant  variation in the  peak area of  standard solution was
observed  up  to  24  hours,  also  no  additional  peak  were  found  in  the  chromatogram
revealing stability of linagliptin in mobile phase. The results were reported in Table: 3.11
and chromatogram of solution stability were represented as Fig: 3.11. and 3.12.
ROBUSTNESS
The robustness was determined by deliberately modifying the experimental conditions.
The  parameters  varied  are  flow  rate  (±10%),  organic  strength  (±7%)  and  buffer
concentration (±12%).
(i)Effect of variation in flow rate:
Mean  ±SD  (n=6)  of  retention  time  (min),  tailing  factor  and  peak  area  (mv.sec)  for
linagliptin was found to be 4.47 ± 0.29, 1.41 ± 0.011 and 1229.697 ± 32.12 respectively.
The results were reported in Table: 3.10.
(ii)Effect of variation in mobile phase composition (acetonitrile):
     Mean± S.D (n=6) of retention time (min), Tailing factor and Peak area (mv.sec) for
linagliptin were 4.52 ± 0.45, 1.29±0.02 and 1221.33 ± 32.72 respectively.  The results
were reported in Table 3.10.
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(iii)Effect of variation of buffer pH in mobile phase:
Mean ± S.D (n=6) of  retention time (min),  tailing factor  and  peak area  (mv.sec)  for
linagliptin was found to be 4.48 ± 0.055, 1.42 ± 0.2 and 1230.33 ± 26.274 respectively.
The results were reported in Table: 3.10.
(iv)Effect of variation in buffer concentration:
Mean± S.D (n=6) of retention time (min), tailing factor and peak area (mv.sec) for 
linagliptin was found to be 4.47 ± 0.05529, 11.42 ± 0.01, 1241.66 ± 18.50 respectively. 
The results were reported in Table 3.10.
The results showed that, none of the significantly influenced the tailing factor  and 
theoretical plates. The retention time was un affected by change in buffer pH, 
concentration, although minor change were found in flow rate and organic strength 
variation, but separation, quantification was not influenced.
LOD & LOQ
     Lowest amount of analyte that can be detected is limit of detection but not necessarily
to be quantified. Lowest amount of analyte that can be detected and is quantified is limit
of quantification. They are determined by performing three sets of calibration curve of
concentrations  ranging  from  6-16µg/mL,  subsequently  calculated  by  using  standard
deviation of y interceptand mean of the slope.LOD is found to be 0.008µg/mLand LOQ
was found to be 0.025µg/mL. Over all the analytical method was very sensitive.  The
results were reported in Table 3.5.
ASSAY
      The  validated  method  was  applied  was  to  the  determination  of  linagliptin  in
commercially available Trajenta tablets. The result of the assays (n=3) undertaken yielded
101% of label claim for linagliptin. The observed concentration of linagliptin was found
to be 5.05mg, which is in good agreement with label claim.The results were shown in
Table: 3.9.
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THE FORCED DEGRADATION STUDIES
     Stress studies were carried out following an ICH guideline which establishes the
requirements of stability indicating methods. Stress testing provides evidence on how the
quality of a drug may be affected under the influence of different stress conditions. Drug
decomposition may result in loss of potency and advent of possible adverse effects due to
the formation of degradation products. The tests were performed on 1mg/mL solution of
linagliptin  using  various  conditions  acidic,  basic  and  oxidizing  conditions.  Thermal
condition was performed on 10mg of linagliptin solid drug for 10 days at 60oC. 
ACID INDUCED DEGRADATION:
Analysis of chromatograms of the acidic degraded samples for linagliptin using 0.1N HCl
either at room temperature or at 60oC temperature demonstrated additional peak at 1.61
min.  employing  1N  HCl  for  degradation  either  at  room  temperature  or  at  60oC
temperature showed additionalpeaks at  1.21 min and 1.62 min. Further,  estimation of
retention times and peak areas illustrated that peaks of degraded products were resolved
from the drug peak and no significant degradation in every condition up to 24hours. The
results were shown in the Fig: 3.18, 3.19, 3.20, 3.21, 3.22, 3.23, 3.24, 3.25, 3.26, 3.27,
3.28 and 3.29.
THERMAL DEGRADATION:
The linagliptin degraded under dry heat conditions showed no additional peaks, this was
confirmed  by  good  peak  area.  This  indicates  linagliptin  is  resistant  to  dry  heat
degradation.The results were shown in theare shown in Fig: 3.14 and 3.15.
OXIDATIVE DEGRADATION:
The  linagliptin  degraded  with  3%  hydrogen  peroxide  showed  no  additional  peaks,
depicting linagliptin resistance to oxidative degradation.The results were shown in the
Fig: 3.16 and 3.17.
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BASE INDUCED DEGRADATION:
     Preliminary base induced degradation revealed linagliptin stability is not significantly
effected by treatment with 0.1N NaOH up to 24 hours at room temperature and 3 hours at
60oC. In these conditions two impurity peaks were observed at 1.3 min and 1.53 min,
were resolved from the drug peak. Further treatment with 1N NaOH for 24 hours at room
temperature resulted in significant degradation, approximately 86% of the drug degraded.
Conducting similar study at higher temperature (60oC), near complete degradation was
observed at 3 hours. The impurities formed, at room temperature eluted at 1.31min and
1.62min retention time, impurities formed at 60oC eluted at 1.2 to 2.1 min retention time.
Interestingly none of them interfered with drug peak.The results were shown in the Fig:
3.30, 3.31, 3.32, 3.33, 3.34, 3.35, 3.36, 3.37, 3.38 and 3.39. Over all summary of base
degradation was shown in the Table: 3.12.
In addition, to know more about 1N  NaOH induced degradation at  60oC, two studies
were conducted. First study duration was 115 minutes, samples were analyzed at every 15
minutes interval.  The results obtained are shown in  Table: 3.13. and  Fig:3.43. Second
study was conducted for 18 minutes duration, samples were analyzed at every 15 minutes
interval.The results obtained are shown in  Table: 3.14. and  Fig:3.47. Both the studies
showed time dependant degradation of linagliptin.
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6. CONCLUSION
The  present  study  describes  sensitive  and  reproducible  method  for  the  quantitative
determinationlinagliptin and its  degradation behavior.  The method was based on high
performanceliquid chromatographic separation of the drug on the MicrosorbC8 (25 cms
long  4.6mm  inner  diameter)column  at  ambient  temperature  using  mobile  phase
potassiumdihydrogen phosphate(40mM: pH 3)  and acetonitrile (70:30, v/v). Flow rate
was 1.0mL/min and retention time was found to be 4.19min. Quantitation was achieved
with  UV  detection  at  225nm  based  on  peak  area  with  linear  calibration  curve  at
concentration  range  0.2  -  16µg/mL.  This  method  has  been  successively  applied  to
pharmaceutical formulation. No chromatographic interference from the tablet excepients
was found. The method was validated.  Relative standard deviation values for  all  key
parameters were less than 2.0%. Excellent recoveries (98.51 and 99.82%) proved that the
method  was  sufficiently  accurate.  The  LOD  and  LOQ  were  found  to  be  0.06  and
0.18µg/mL,  respectively.  The RSD valves  for  intraday and  inter-day precision below
2.0%. Acceptable robustness indicates that the assay method remains unaffected by small
but deliberate variations.
Further  more,  developed  method  was  suitable  to  study  the  degradation  behavior  of
linagliptin under acid, alkali, oxidation and thermal conditions. The linagliptin was found
to be degraded in alkaline conditions in time dependant manner. Future studies aiming on
isolation and characterization of formed impurities may provide further insights.
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